Published
October 3, 2025
Updated
June 12, 2026
If you or a loved one took Oxbryta for sickle cell disease and suffered serious complications, here is where the recall stands and what the reported lawsuits and settlement activity mean.
What's the Pfizer Sickle Cell Oxbryta Recall and Lawsuit?
Oxbryta, a drug initially hailed as a breakthrough for sickle cell disease treatment, was voluntarily withdrawn from the market by Pfizer in 2024. Post-marketing clinical trials revealed that the drug's benefits no longer outweighed the risks, with a higher rate of vaso-occlusive crises (also known as "VOCs") and fatal events among patients taking Oxbryta compared to those receiving a placebo. This discovery led to Pfizer's decision to halt distribution and discontinue all clinical trials, and the FDA recommending that healthcare professionals stop prescribing the drug.The withdrawal has been followed by individual personal-injury lawsuits against Pfizer and Global Blood Therapeutics, alleging the companies failed to adequately investigate and disclose the drug's potential risks, along with a related putative class/economic-loss case. There is no single centralized class action claim process to "join" — people who experienced severe complications such as VOCs, strokes, or severe pain while taking Oxbryta would generally pursue their own individual claims. Patients who were taking Oxbryta are advised to consult with their doctors to discuss alternative treatment options.
Status
Withdrawn from Market · Lawsuits Filed · Settlement Activity Reported
Pfizer voluntarily withdrew Oxbryta in 2024. Individual personal-injury lawsuits and a related putative class/economic-loss case have been filed, and some related federal cases report settlement-in-principle activity
Claim Deadline
No public claim deadline confirmed
No public Oxbryta settlement claim form or approved settlement filing path has been confirmed from the reviewed sources
Potential Payout
Varies
Any individual recovery would depend on the facts of the case, including the severity of complications, hospitalizations, lasting injury, and whether a person is represented in litigation or included in any future approved settlement
What is Pfizer Oxbryta?
Oxbryta (voxelotor), launched in 2019, was initially hailed as a promising treatment for sickle cell anemia, a genetic blood disorder causing red blood cells to deform and obstruct blood flow, leading to severe pain and organ damage. The drug's approval by the FDA was expedited due to its potential to address a significant unmet medical need.Safety Concerns and Recall
However, in 2024, Pfizer, the company that acquired Oxbryta's developer, Global Blood Therapeutics, announced a voluntary recall of the drug. This decision followed reports of severe side effects, including vaso-occlusive crises (VOCs), strokes, and even fatalities in some patients.What Is the Current Status of the Oxbryta Lawsuits?
Oxbryta was withdrawn from the market in 2024 after data suggested the overall benefit no longer outweighed the risk in the approved sickle cell patient population, including an imbalance in vaso-occlusive crises and fatal events. Since then, individual personal-injury lawsuits and a related putative class/economic-loss case have been filed in federal court, and some related federal cases have reported settlement-in-principle activity on their dockets. That settlement activity does not mean there is an open claim form, an approved class settlement, or a guaranteed payout — no public Oxbryta claim form or approved consumer payout process has been confirmed from the reviewed sources.Is There an Oxbryta Settlement or Claim Form?
No. As of this update, no court-approved Oxbryta class action settlement or public claim form has been confirmed. Several related federal cases have reported settlement-in-principle activity — meaning the parties told the court they reached, or are working toward, a resolution — but a settlement in principle is not the same as an approved settlement with a public claims process. Oxbryta lawsuits are not currently the same thing as an open class action settlement claim form. People who believe they were injured should not wait for a class action claim form to appear; deadlines can vary by state and individual facts, so consider speaking with your own attorney promptly.What Cases Have Been Filed?
Among the Oxbryta cases filed in federal court is Frazier v. Global Blood Therapeutics, Inc. and Pfizer, Inc., No. 3:25-cv-04027-TLT, an individual personal-injury lawsuit filed on May 8, 2025 in the U.S. District Court for the Northern District of California before Judge Trina L. Thompson. The complaint alleges strict liability for design defect and failure to warn, negligence, negligent misrepresentation, breach of express and implied warranties, unjust enrichment, and violations of the New Jersey Consumer Fraud Act, and alleges the plaintiff suffered repeated vaso-occlusive crises requiring multiple hospitalizations while taking Oxbryta. The docket later reflected a Notice of Settlement filed on October 9, 2025 — so Frazier is no longer simply an active pending lawsuit.Related federal cases include Allen v. Global Blood Therapeutics, Inc., No. 3:24-cv-07786-TLT, another Oxbryta case in the Northern District of California in which the parties reported settlement-in-principle activity, and Jolly v. Global Blood Therapeutics, Inc., No. 3:24-cv-09345-TLT, a putative class/economic-loss case that also reported a settlement in principle and work toward court approval procedures. An August 2025 joint case management statement referenced additional Oxbryta litigation, including Frazier, Ford, Marvin Cosey, and 14 served state-court product-liability cases involving alleged personal injuries from Oxbryta. Public sources reviewed did not confirm an open public claim form as of this update.
What Should Patients Do If They Took Oxbryta?
Patients who were taking Oxbryta should consult their healthcare providers about alternative treatment options. People who believe they experienced severe complications after taking Oxbryta — such as VOCs, strokes, hospitalizations, or lasting injury — should gather prescription records, medical records, and hospitalization records, and may want to contact their own product-liability or medical-injury attorney. Do not wait for a class action notice if you believe you may have an individual legal claim, because deadlines can vary by state and individual facts.What Was the FDA's Response?
The FDA (The U.S. Food and Drug Administration), which initially approved Oxbryta under an accelerated pathway, conducted a safety review of post-marketing data. The review revealed a higher rate of VOCs and deaths among patients taking Oxbryta compared to those receiving a placebo. Based on these findings, the FDA recommended that healthcare professionals stop prescribing Oxbryta and that patients discuss alternative treatments with their doctors.What Has Pfizer's Response Been to the Oxbryta Fallout?
In response to the safety concerns, Pfizer not only withdrew Oxbryta from the market but also halted all ongoing clinical trials and expanded access programs for the drug. The company stated that its decision was based on a comprehensive review of clinical data, which indicated that the benefits of Oxbryta no longer outweighed the risks for sickle cell patients.What is the Total Settlement Amount?
No public total settlement amount or approved consumer payout fund has been confirmed from the reviewed sources. Several related federal cases have reported settlement-in-principle activity, but that is not the same as an approved public claim form or a confirmed class-action payout process.How Do I Qualify For a Payout?
There is no public Oxbryta claims process to qualify for at this time. In individual personal-injury lawsuits, recovery generally depends on having been prescribed Oxbryta for sickle cell disease and having developed severe complications such as VOCs, strokes, hospitalizations, or lasting injury — and on the specific facts of each person's case.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
How Much Can I Get Paid?
Any individual recovery would depend on the facts of the case, including the severity of complications, hospitalizations, lasting injury, and whether a person is represented in litigation or included in any future approved settlement. No payout amounts have been publicly confirmed.How Do I File a Claim?
No public Oxbryta claim form has been confirmed. People who believe they experienced severe complications after taking Oxbryta should gather prescription records, medical records, hospitalization records, and documentation of VOCs or other complications, and may want to contact their own product-liability or medical-injury attorney. Do not wait for a class action notice if you believe you may have an individual legal claim, because deadlines can vary.Disclaimer
OpenClassActions.com is not a law firm and does not represent users or provide legal advice. We cannot guarantee that any attorney will respond to an inquiry. If you believe time-sensitive legal rights may be involved, seek your own attorney promptly, as filing deadlines can vary by state and by the facts of your case.Filing Class Action Settlement Claims
Please note that your claim form will be rejected if you submit a settlement claim for payout with any fraudulent information. By providing this information and your sworn statement of its veracity, you agree to do so under the penalty of perjury. You would also be harming others that actually qualify for the class action settlement. If you are not sure whether or not you qualify for this class action settlement, visit the class action administrator's website below. OpenClassActions.com is only providing information and is not a class action administrator or a law firm. OpenClassActions is a participant in the Amazon affiliate advertising program and this post may contain affiliate links, which means we may earn a commission or fees if you make a purchase via those links.Sources
• Pfizer Press Release — Voluntary Withdrawal of All Lots of Oxbryta (Sept. 25, 2024)• FDA Safety Alert — Voluntary Withdrawal of Oxbryta from the Market (Sept. 26, 2024)
• Justia Docket — Frazier v. Global Blood Therapeutics, Inc. et al., No. 3:25-cv-04027 (N.D. Cal.)
• Justia Docket — Allen v. Global Blood Therapeutics, Inc. et al., No. 3:24-cv-07786 (N.D. Cal.)
• Allen — Notice of Settlement (Oct. 2025)
• Allen — Joint Status Report re Settlement (Apr. 16, 2026)
• Jolly — Joint Request / Settlement Update (Dec. 2025)
• Joint Case Management Statement re Related Oxbryta Cases (Aug. 2025)
For more class actions keep scrolling below.
Drug
Oxbryta (voxelotor)
Defendants
Global Blood Therapeutics, Inc. & Pfizer, Inc.
Market Withdrawal
September 25, 2024 (voluntary, worldwide)
Example Case
Frazier v. Global Blood Therapeutics, Inc., et al.
Case Number
3:25-cv-04027 (N.D. Cal.)
Court
U.S. District Court, Northern District of California
Status
Lawsuits filed · settlement activity reported in related federal cases · no public claim form confirmed
